Current status of targeted therapy in non-small cell lung cancer

Drugs of Today

Volumn 50, Issue 7, 2014, Pages 503-525

  Parums, Dinah V ^a  

^a NONE

Author keywords

Biomarkers; EGFR; HER2; Non small cell lung cancer; Targeted therapy

Indexed keywords

AFATINIB; ALECTINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOSIMILAR AGENT; CERITINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DACOMITINIB; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; ICOTINIB; LAPATINIB; NECITUMUMAB; NERATINIB; NINTEDANIB; ONARTUZUMAB; PALBOCICLIB; RAMUCIRUMAB; SELUMETINIB; SORAFENIB; TIVANTINIB; TRAMETINIB; TRASTUZUMAB; TUMOR MARKER; VANDETANIB; VEMURAFENIB;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DRUG MARKETING; DRUG MECHANISM; DRUG RESISTANCE; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); MICROSCOPY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

BIOMARKERS; EGFR; HER2; NON-SMALL CELL LUNG CANCER; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 85047687980     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.07.2185913     Document Type: Review

References (98)

1. The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract 2014, 10(2): 119-42.
2. Grossi, F. Management of non-small cell lung in cancer patients with stable disease. Drugs 2012, 72(Suppl. 1): 20-7.
3. Azzoli, C.G., Temin, S., Aliff, T. et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2011, 29(28): 3825-31.
4. Sandler, A., Gray, R., Perry, M.C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24): 2542-50. (Pubitemid 44917502)
5. Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Jr. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(31): 5034-42. (Pubitemid 46631407)
6. Hirsch, F.R., Dziadziuszko, R., Thatcher, N. et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced non-small-cell lung cancer. Cancer 2008, 112(5): 1114-21. (Pubitemid 351304597)
7. Donovan, M.J., Kotsianti, A., Bayer-Zubek, V. et al. A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. Eur J Cancer 2009, 45(8): 1518-26.
8. Mansfield, E.A. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014, 20(6): 1453-7.
9. Fridlyand, J., Simon, R.M., Walrath, J.C. et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013, 12(10): 743-55.
10. Lindeman, N.I., Cagle, P.T., Beasley, M.B. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013, 15(4): 415-53.
11. Lindeman, N.I., Cagle, P.T., Beasley, M.B. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013, 137(6): 828-60.
12. Lynch, T.J., Bell, D.W., Sordella, R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21): 2129-39. (Pubitemid 38637993)
13. Li, A.R., Chitale, D., Riely, G.J. et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008, 10(3): 242-8. (Pubitemid 351692167)
14. D'Arcangelo, M., Cappuzzo, F. Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2013, 13(5): 523-33.
15. Ibrahim, E.M. Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Ann Thorac Med 2010, 5(3): 153-60.
16. Morabito, A., Piccirillo, M.C., Falasconi, F. et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14(4): 378-90.
17. Herbst, R.S., Sun, Y., Eberhardt, W.E. et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7): 619-26.
18. Morabito, A., Piccirillo, M.C., Costanzo, R. et al. Vandetanib: An overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc) 2010, 46(9): 683-98.
19. Landi, L., Cappuzzo, F. Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res 2013, 2(1): 40-9.
20. Tan, F., Shen, X., Wang, D. et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76(2): 177-82.
21. Shi, Y., Zhang, L., Liu, X. et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013, 14(10): 953-61.
22. Mok, T., Lee, K., Tang, M., Leung, L. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. Future Oncol 2014, 10(5): 813-22.
23. Hilberg, F., Roth, G.J., Krssak, M. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68(12): 4774-82.
24. Reck, M., Kaiser, R., Mellemgaard, A. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014, 15(2): 143-55.
25. Pirker, R. EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol 2013, 8(1): 47-53.
26. Pirker, R., Pereira, J.R., Szczesna, A. et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674): 1525-31.
27. Pirker, R., Pereira, J.R., von Pawel, J. et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1): 33-42.
28. Kim, E.S., Neubauer, M., Cohn, A. et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013, 14(13): 1326-36.
29. Merck withdraws European filing for Erbitux in NSCLC [news release]. Merck KGaA, September 18, 2012. Accessed July 22, 2014.
30. Dienstmann, R., Felip, E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011, 11(9): 1223-31.
31. Lilly announces phase III necitumumab study meets primary endpoint of overall survival [news release]. Eli Lilly and Company, August 13, 2013. Accessed July 22, 2014.
32. Mazieres, J., Peters, S., Lepage, B. et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31(16): 1997-2003.
33. Arcila, M.E., Chaft, J.E., Nafa, K. et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012, 18(18): 4910-8.
34. Yan, M., Parker, B.A., Schwab, R., Kurzrock, R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014, 40(6): 770-80.
35. Tartarone, A., Lerose, R., Lazzari, C., Gregorc, V., Aieta, M. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? Med Oncol 2014, 31(8): 78.
36. Wong, K.K., Fracasso, P.M., Bukowski, R.M. et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15(7): 2552-8.
37. Bose, P., Ozer, H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2009, 18(11): 1735-51.
38. Gandhi, L., Bahleda, R., Tolaney, S.M. et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014, 32(2): 68-75.
39. Diaz, R., Nguewa, P.A., Parrondo, R. et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010, 10: 188.
40. Solca, F., Dahl, G., Zoephel, A. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343(2): 342-50.
41. Wu, Y.L., Zhou, C., Hu, C.P. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15(2): 213-22.
42. Yang, J.C., Hirsh, V., Schuler, M. et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27): 3342-50.
43. Liang, W., Wu, X., Fang, W. et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 2014, 9(2): e85245.
44. Cataldo, V.D., Gibbons, D.L., Perez-Soler, R., Quintas-Cardama, A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364(10): 947-55.
45. Lauro, S., Onesti, C.E., Righini, R., Marchetti, P. The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res 2014, 34(4): 1537-45.
46. Zhu, J., Sharma, D.B., Gray, S.W., Chen, A.B., Weeks, J.C., Schrag, D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012, 307(15): 1593-601.
47. The top 25 best-selling drugs of 2013. Genetic Eng & Biotech News, March 3, 2014. Accessed July 22, 2014.
48. Laskin, J., Crino, L., Felip, E. et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 2012, 7(1): 203-11.
49. Poole, R.M., Vaidya, A. Ramucirumab: first global approval. Drugs 2014, 74(9): 1047-58.
50. Garon, E.B., Cao, D., Alexandris, E., John, W.J., Yurasov, S., Perol, M. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer 2012, 13(6): 505-9.
51. Grande, E., Bolos, M.V., Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011, 10(4): 569-79.
52. Wu, S.G., Kuo, Y.W., Chang, Y.L. et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012, 7(1): 98-104.
53. Minca, E.C., Portier, B.P., Wang, Z. et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013, 15(3): 341-6.
54. Cui, J.J., Tran-Dube, M., Shen, H. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011, 54(18): 6342-63.
55. Shaw, A.T., Kim, D.W., Nakagawa, K. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25): 2385-94.
56. Friboulet, L., Li, N., Katayama, R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014, 4(6): 662-73.
57. Shaw, A.T., Kim, D.W., Mehra, R. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370(13): 1189-97.
58. Ignatius Ou, S.H., Azada, M., Hsiang, D.J. et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014, 9(4): 549-53.
59. Seto, T., Kiura, K., Nishio, M. et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14(7): 590-8.
60. Rocca, A., Farolfi, A., Bravaccini, S., Schirone, A., Amadori, D. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother 2014, 15(3): 407-20.
61. Pfizer's palbociclib (PD-0332991) receives Food and Drug Administration breakthrough therapy designation for potential treatment of patients with breast cancer [news release]. Pfizer Inc., April 9, 2013. Accessed July 17, 2014.
62. Zhang, J., Gold, K.A., Kim, E. Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs 2012, 21(9): 1417-26.
63. Imielinski, M., Greulich, H., Kaplan, B. et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 2014, 124(4): 1582-6.
64. Janne, P.A., Shaw, A.T., Pereira, J.R. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1): 38-47.
65. Garon, E.B., Finn, R.S., Hosmer, W. et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010, 9(7): 1985-94.
66. Wright, C.J., McCormack, P.L. Trametinib: first global approval. Drugs 2013, 73(11): 1245-54.
67. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8029.
68. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8028.
69. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8027.
70. Sequist, L.V., Heist, R.S., Shaw, A.T. et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011, 22(12): 2616-24.
71. Ohashi, K., Sequist, L.V., Arcila, M.E. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012, 109(31): E2127-33.
72. Ballantyne, A.D., Garnock-Jones, K.P. Dabrafenib: first global approval. Drugs 2013, 73(12): 1367-76.
73. Swaika, A., Crozier, J.A., Joseph, R.W. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther 2014, 8: 775-87.
74. Peters, S., Michielin, O., Zimmermann, S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 2013, 31(20): e341-4.
75. Nakamura, Y., Niki, T., Goto, A., Morikawa, T., Miyazawa, K., Nakajima, J., Fukayama, M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007, 98(7): 1006-13. (Pubitemid 46865384)
76. Ichimura, E., Maeshima, A., Nakajima, T., Nakamura, T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996, 87(10): 1063-9. (Pubitemid 26392044)
77. Ou, S.H., Kwak, E.L., Siwak-Tapp, C. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6(5): 942-6.
78. Arriola, E., Conde-Estévez, D. Onartuzumab. Anti-HGFR (c-Met) monoclonal antibody, Oncolytic. Drugs Fut 2014, 39(6): 403-8.
79. Spigel, D.R., Ervin, T.J., Ramlau, R.A. et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013, 31(32): 4105-14.
80. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014, Abst 8000.
81. Roche provides update on phase III study of onartuzumab in people with specific type of lung cancer [news release]. Roche, March 3, 2013. Accessed July 22, 2014.
82. Sequist, L.V., von Pawel, J., Garmey, E.G. et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29(24): 3307-15.
83. Scagliotti, G.V., Novello, S., Schiller, J.H. et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012, 13(5): 391-5.
84. ArQule provides updates on clinical trials in hepatocellular carcinoma and non-small cell lung cancer with tivantinib [news release]. ArQule, Inc., January 16, 2014. Accessed July 22, 2014.
85. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(7417): 519-25.
86. Wang, R., Hu, H., Pan, Y. et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012, 30(35): 4352-9.
87. Tsuta, K., Kohno, T., Yoshida, A., Shimada, Y., Asamura, H., Furuta, K., Kushima, R. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer 2014, 110(6): 1571-8.
88. Kim, H.S., Mitsudomi, T., Soo, R.A., Cho, B.C. Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 2013, 80(3): 249-55.
89. Kim, H.R., Kim, D.J., Kang, D.R. et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013, 31(6): 731-7.
90. Jamal-Hanjani, M., Hackshaw, A., Ngai, Y. et al. Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biol 2014, 12(7): e1001906.
91. Carrato, A., Vergnenegre, A., Thomas, M., McBride, K., Medina, J., Cruciani, G. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin 2014, 30(3): 447-61.
92. Kim, E.S., Herbst, R.S., Wistuba, II et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1(1): 44-53.
93. Blumenschein, G.R., Jr., Saintigny, P., Liu, S. et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013, 19(24): 6967-75.
94. Torjesen, I. Large personalised medicine trial in lung cancer heralds new research partnership. BMJ 2014, 348: g2837.
95. Harrison, C. Trial watch: lung cancer trial aims to bolster personalized medicine. Nat Rev Drug Discov 2014, 13(6): 407.
96. Kris, M.G., Johnson, B.E., Berry, L.D. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311(19): 1998-2006.
97. Reichert, J.M. Antibodies to watch in 2014: Mid-year update. MAbs 2014, 6(4): 799-802.
98. Rak Tkaczuk, K.H., Jacobs, I.A. Biosimilars in oncology: from development to clinical practice. Semin Oncol 2014, 41(Suppl. 3): S3-S12.